US healthcare stocks moved higher on Tuesday as a flurry of dealmaking and product news gave investors fresh reasons to bid up the sector. The main catalyst was a Bloomberg report that private equity firm EQT had made a binding offer of more than $50 a share for Qiagen, a Dutch diagnostic-testing company. That news, along with a separate acquisition in the prenatal testing space, helped push the NYSE Healthcare Index up 2.4%, while the Health Care Select Sector SPDR Fund (XLV) gained 2.2% and the iShares Biotechnology ETF (IBB) added 2.6%.
Qiagen in the spotlight
Qiagen, which makes tools and tests used in molecular diagnostics, has been a frequent subject of takeover speculation. The Bloomberg report said the company is in advanced talks with EQT after receiving a binding offer above $50 per share, and that KKR has also made a bid. Qiagen shares jumped 5.8% on the news.
For investors, the key detail is that the offer is described as binding. That means the buyer has committed to a specific price, rather than just expressing interest. Once a binding bid is on the table, the stock price often starts trading like a set of odds: the upside is capped by the offer price, while the downside depends on what investors think the business is worth if the deal fails. That dynamic can narrow the gap between the market price and the bid, because “will it close?” matters more than day-to-day sentiment.
The mention of a second bidder, KKR, adds another layer. When more than one buyer is circling, it can push the final price higher or increase the chances that a deal gets done. It also signals that private equity sees value in diagnostics, a sector that has been a consistent target for takeovers in recent years.
Labcorp buys Myriad's prenatal unit
Separately, Labcorp, a US diagnostics company, said it will buy Myriad Genetics’ prenatal health testing business for $210 million in cash, plus the value of inventory at closing. The deal gives Labcorp a foothold in a growing area of genetic testing that screens for conditions in unborn babies. Myriad shares surged 36% on the news, while Labcorp rose about 1%.
For Myriad, the sale is a way to raise cash and focus on its core oncology and other testing lines. For Labcorp, it’s an expansion of its testing menu at a time when demand for genetic and diagnostic services remains strong. The modest gain in Labcorp’s stock suggests investors see the deal as sensible but not transformative.
GeneDx adds new sequencing capability
Another mover was GeneDx, which rose after saying it plans to add long-read whole genome sequencing to its testing lineup. That’s a more advanced form of genetic analysis that can spot structural changes in DNA that standard short-read sequencing might miss. It’s a reminder that healthcare stocks can move on both M&A and new clinical capabilities, as investors bet on future revenue from innovative tests.
What it means for investors
For everyday investors, the day’s moves illustrate a few broader points. First, healthcare is a sector where deal activity can create sharp, stock-specific moves. When a company like Qiagen becomes a takeover target, its shares can jump quickly, but the potential gain is limited by the offer price. That’s why chasing a stock after a bid is announced can be risky.
Second, when a large private-equity buyer shows up in diagnostics — and a second bidder is mentioned — it can reset expectations for more takeovers across the healthcare and biotech universe. That’s one reason broad funds like IBB and XLV can catch a bid even when only a handful of companies are in the headlines. Investors who own these funds get exposure to a basket of stocks, which can smooth out the volatility of individual deal stories.
Finally, the Labcorp-Myriad deal highlights the ongoing consolidation in genetic testing. As technology improves and costs fall, larger companies often look to buy smaller players to expand their offerings. That can be good news for shareholders of acquisition targets, but it also means competition is intensifying.
Looking ahead, investors will likely watch for any official confirmation from Qiagen or EQT, as well as regulatory reviews of the Labcorp-Myriad transaction. The broader healthcare sector has been a relative haven in uncertain markets, and continued deal flow could keep supporting prices. For those with a long-term view, the sector’s mix of defensive demand and innovation-driven growth remains a key reason it often appears in diversified portfolios.
As always, it’s worth remembering that individual stock moves can be driven by speculation, and not every rumor turns into a completed deal. But for now, the market is clearly betting that more consolidation is on the way.
